A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial

Melanie J Davies,1 Laura J Gray,2* Dariush Ahrabian,3 Marian Carey,4 Azhar Farooqi,1 Alastair Gray,3 Stephanie Goldby,4 Sian Hill,4 Kenneth Jones,5 Jose Leal,3 Kathryn Realf,4 Timothy Skinner,6 Bernie Stribling,4 Jacqui Troughton,4 Thomas Yates1 and Kamlesh Khunti1 on behalf of the Let’s Prevent Diabetes Team

1Diabetes Research Centre, University of Leicester, Leicester, UK
2Department of Health Sciences, University of Leicester, Leicester, UK
3Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
4Leicester Diabetes Centre, University Hospitals of Leicester, Leicester, UK
5Patient and Public Involvement Group, Leicester Diabetes Centre, Leicester, UK
6School of Psychological and Clinical Sciences, Charles Darwin University, Darwin, NT, Australia

*Corresponding author

Declared competing interests of authors: Melanie Davies has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Eli Lilly and Company, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen, and as a speaker for Mitsubishi Tanabe Pharma Corporation. She has received grants in support of investigator and investigator-initiated trials from Novo Nordisk, Sanofi-Aventis and Eli Lilly and Company. She has received grants and support from the National Institute for Health Research (NIHR) during the conduct of this study. Alastair Gray reports grants from NIHR during the conduct of the study. Kamlesh Khunti reports that he has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Eli Lilly and Company and Merck Sharp & Dohme. He has received grants in support of investigator and investigator-initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Eli Lilly and Company, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme. Kamlesh Khunti has received funds for research, honoraria for speaking at meetings and has served on advisory boards for Eli Lilly and Company, Sanofi-Aventis, Merck Sharp & Dohme and Novo Nordisk.

Published January 2017
DOI: 10.3310/pgfar05020
Scientific summary

A community-based primary prevention programme for T2DM
Programme Grants for Applied Research 2017; Vol. 5: No. 2
DOI: 10.3310/pgfar05020

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

The number of people diagnosed with type 2 diabetes mellitus (T2DM) is reaching epidemic proportions. The rising number of cases and the associated health-care costs mean that diabetes mellitus prevention is one of the most significant and pressing health challenges of our time. It is well established that prior to an individual being diagnosed with T2DM there is a period of impaired glucose regulation, often referred to as prediabetes mellitus (PDM). Interventions targeted at this PDM stage have the potential to slow down progression to T2DM; however, as many individuals with PDM are asymptomatic, often individuals will not present to a health-care practitioner until T2DM has been established for some time. Therefore, one of the key elements of a successful prevention programme is the development of a screening tool that can accurately identify those individuals at highest risk of T2DM. Once identified, an effective programme needs to be employed to help individuals to address and modulate their risk. Although several initiatives to promote preventative measures have been developed over recent years, there has been a lack of empirical data when testing prevention programmes in a real-world routine care setting. In addition, evidence on the cost-effectiveness of such programmes is sparse.

Objectives

The objectives of the study were to:

- develop and validate a risk score to identify those who require diagnostic testing, to identify undiagnosed T2DM and to identify those at high risk of future T2DM and cardiovascular disease in a multiethnic population
- use this risk score to identify and engage those at highest risk of T2DM and offer them a lifestyle self-management programme with the aim of reducing the risk of progression to T2DM and reducing cardiovascular risk
- pilot and test a lifestyle self-management programme based on group care, targeting five key areas, using information currently collated from the European Union-funded Diabetes in Europe Prevention using Lifestyle, physical Activity and Nutritional intervention project
- develop a training and quality-assurance programme for community-based health trainers, who may include health-care professionals, to deliver the initial programme and provide ongoing support to those at highest risk of T2DM
- explore the lifestyle self-management programme and its cost-effectiveness
- explore how a two-stage screening programme and prevention intervention can be implemented in primary care.

Development of the intervention

This structured education intervention has been developed to meet the current need for an evidence-based diabetes mellitus prevention programme that meets current National Institute for Health and Care Excellence (NICE) recommendations and which can be implemented within a UK health-care setting. The intervention encourages self-management of PDM, using simple, non-technical language and visual aids. The Diabetes Education and Self-Management for Ongoing and Newly Diagnosed programme was the first national education programme for people with T2DM to meet NICE criteria and has been used as a basis for the development of the Let’s Prevent programme. The development process was informed by the Medical Research Council framework. An iterative cycle (including initial development, piloting, collecting
and collating qualitative and quantitative data, reflection and modification of the intervention) was used to inform and refine the lifestyle intervention until it was considered fit for purpose for evaluation in the randomised controlled trial (RCT).

**Methods**

The study consisted of two phases. Phase one included the development and validation of a risk score that could be applied within a primary care practice, using routinely available data to identify individuals at high risk of T2DM. This risk score was then used to identify people at high risk of T2DM for invitation to screening.

**Phase one: two-stage screening study using a risk score**

The Leicester Practice Risk Score (LPRS) was developed using data from a completed population-based screening study conducted in the same location as this study. It was validated using data from a second screening study. The risk score was designed for use in primary care and, therefore, included only routinely available risk factors. The risk score included age, sex, ethnicity, body mass index (BMI), family history of diabetes mellitus and antihypertensive medication. The score was found to have high levels of discrimination and calibration. A piece of software was developed that enabled the risk score to be easily used in primary care.

For the screening study, the risk score was applied to data from 44 practices. The top 10% of patients with the highest score were invited for screening. Following an informed consent process, a number of clinical assessments and measurements were performed. All participants undertook an oral glucose tolerance test (OGTT). All participants identified as having PDM took part in the RCT, with the screening data forming the baseline assessment for the trial. PDM was defined as fasting plasma glucose > 6.1 mmol/l but < 7.0 mmol/l, or a 2-hour post-glucose reading > 7.8 mmol/l but < 11.1 mmol/l. If a participant had an OGTT result in the range for diabetes mellitus, they were recalled for a second confirmatory test. In accordance with the World Health Organization criteria, diabetes mellitus was defined as a fasting blood glucose ≥ 7.0 mmol/l and/or 2-hour plasma glucose of ≥ 11.1 mmol/l. Any participant found to have diabetes mellitus at baseline was excluded from the study and returned to their general practitioner (GP) for commencement of standard care.

Other samples collected were lipids, liver function tests, glycated haemoglobin (HbA1c), biomarkers and whole genetic blood samples. A number of anthropometric data were also collected; these consisted of weight, BMI, waist circumference, hip circumference and blood pressure (using the average of three readings). The 7-day step count was assessed using a sealed piezoelectric pedometer (NL-800; New Lifestyles Inc., Lee’s Summit, MO, USA). A questionnaire was also administered, which consisted of a number of validated tools to assess various aspects of diet, physical activity and psychosocial well-being. The Dietary Instrument for Nutrition Education was used to assess dietary fat and fibre intake; the Health State Descriptive System and European Quality of Life-5 Dimensions (EQ-5D) explored quality of life; the Hospital Anxiety & Depression Scale examined depression and anxiety; the Brief Illness Perception Questionnaire looked at cognitive and emotional representations of illness; and the International Physical Activity Questionnaire (short form) determined health-related physical activity.

**Outcome measures**

The primary outcome of the screening phase was the proportion of people detected with PDM or T2DM using the LPRS (positive predictive value). Secondary outcomes included the response rate to the invitation to screening. Those with PDM took part in phase two, that is, the diabetes mellitus prevention cluster RCT.
**Phase two: diabetes mellitus prevention cluster randomised controlled trial study design**

Phase two was a cluster RCT providing a structured intervention for people with PDM, with randomisation at practice level to negate contamination between individual participants. The practices were randomly assigned 1:1 to either the standard care or the intervention arm by a researcher, who was independent of the study team, using stratification by list size (<6000, \( \geq 6000 \)) and ethnicity (percentage South Asian <21%, \( \geq 21\% \)). Phase two was designed to adhere to internationally recognised criteria for developing complex interventions and for undertaking and reporting cluster RCTs.

Participants within the standard care practices were managed by national guidelines for the condition, whereby participants were given an information booklet and general lifestyle advice by their GP or practice nurse. The booklet gave information on risk factors for T2DM and discussed how dietary and lifestyle changes and increased physical activity could be used to prevent progression of the disease.

Participants in the intervention practices were given the same written information as the control group and were also invited to attend ‘Let’s Prevent’, which was a 6-hour structured group education session. In addition, they received a telephone call every 3 months from nursing staff, trained to offer ongoing support in behaviour change and to encourage participants to achieve their individual goals. Finally, each participant within the intervention arm was invited to attend a 3-hour refresher session once per year.

**The intervention**

The structured group education programme was named Let’s Prevent, and sessions followed a detailed written curriculum. It consisted of 1 full day (6 hours) or 2 half-days (3 hours each). For black and minority ethnic groups in which the English language was not readily spoken, four sessions of 3 hours each were delivered by educators and interpreters.

**Outcome measures**

The primary outcome was progression to diabetes mellitus at 3 years in people with screen-detected PDM.

The main secondary outcomes included:

- changes in participant’s glucose levels: HbA\textsubscript{1c}, blood glucose levels fasting and post-glucose load
- change in cardiovascular risk as calculated by the Framingham risk calculator
- 7-day step count
- presence of metabolic syndrome as defined by the National Cholesterol Education Program Adult Treatment Panel III
- cost-effectiveness of the intervention.

All outcomes recorded at the screening visit (listed above), which form the baseline data for the trial, were also collected at 6, 12, 24 and 36 months.

**Inclusion criteria**

- Diagnosed with PDM.
- Aged 40–75 years if English speaking, or 25–75 years if South Asian.
- Able to attend group education sessions.

**Exclusion criteria**

- Unable to give consent.
- Unable to attend group education sessions.
- Diagnosed with diabetes mellitus at screening.
- Required an interpreter for a language other than a South Asian one.
Sample size and statistical methods
Assuming a 3-year cumulative conversion rate to T2DM of 35% in the control group, an intraclass correlation of 0.05, an average of 17 participants per practice and a dropout rate of 20%, we calculated that we would need 374 participants per group to detect a 40% risk reduction in the intervention group (data from 44 practices, with 80% power at the 5% significance level). Analysis of the primary outcome was on an intention-to-treat basis. The event rate per 1000 person-years was calculated by intervention group. Cox proportional hazards models with the intervention group as a covariate were fitted; practices were assumed to have the same frailty. Hazard ratios (HR) along with their 95% confidence intervals (CIs) were presented. The analysis was repeated excluding those from the intervention group who did not attend the education sessions (per-protocol analysis). All other outcomes were analysed using a multilevel model taking into account the practice-level clustering.

Cost-effectiveness analysis
A within-trial cost-effectiveness analysis of the trial results was conducted, using resource use information collected as part of the study and using quality-adjusted life-years (QALYs) as our primary outcome measure. QALYs were calculated as the mean of the utility scores (from EQ-5D or health-state descriptive system) at the start and end of the year, or as the mean at the start, end and 6-month point in the case of the first year. The intervention cost (£200.34) was the total cost of providing the initial intervention, refreshers and support over the 3-year trial period. One-off costs, such as educator training and teaching materials, were also included in the intervention cost calculation. Information on health-care use was recorded via participant self-reports in an economic questionnaire administered at 12-, 24- and 36-month follow-up points. Analysis did not include inpatient costs. We calculated an incremental cost-effective ratio (ICER) by dividing the mean cost difference between intervention and standard care groups by the mean QALY difference. We report the probability that the intervention is the most cost-effective option at a threshold of £20,000 per QALY gained.

Results
A total of 17,972 individuals from 44 practices identified through the risk score as being at high risk of T2DM were invited for screening, of whom 3449 (19.2%) attended. All received a 75-g OGTT. PDM was detected in 880 (25.5%) of those screened. Those with PDM were included in the trial; 36% were female, the average age was 64 years and 16% were from an ethnic minority group. Of those included in the trial, 131 participants developed T2DM over the 3-year follow-up period. There was a 26% reduced risk of developing T2DM in the intervention arm compared with standard care, but this did not reach statistical significance (HR 0.74, 95% CI 0.48 to 1.14; p = 0.18). This was increased when analysing per-protocol (HR 0.65, 95% CI 0.41 to 1.03; p = 0.07). There were also statistically significant improvements in HbA1c, low-density lipoprotein cholesterol, psychosocial well-being, sedentary time and step count. The intervention was found to result in a net gain of 0.046 QALYs over 3 years at an overall cost of £168 per patient, with an ICER of £3643 and a probability of 0.86 of being cost-effective at a willingness-to-pay threshold of £20,000.

Conclusions
We have developed and validated a risk score for detecting those at high risk of undiagnosed PDM/T2DM. We have screened > 3400 people using a two-stage screening programme. The RCT showed that a relatively low-resource pragmatic programme fit for implementation in the UK NHS may lead to a reduction in T2DM and improved biomedical and psychosocial outcomes, and is cost-effective. Future research should focus on increasing attendance to both screening and prevention programmes and offering the programme in different modalities, such as web-based modalities.
Study registration

This trial is registered as ISRCTN80605705.

Funding

Funding for this study was provided by the Programme Grants for Applied Research programme of the National Institute for Health Research.
Programme Grants for Applied Research

ISSN 2050-4322 (Print)
ISSN 2050-4330 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Programme Grants for Applied Research journal

Reports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Programme Grants for Applied Research programme

The Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.

The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.

For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-for-applied-research.htm

This report

The research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0606-1272. The contractual start date was in August 2007. The final report began editorial review in January 2015 and was accepted for publication in November 2015. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PGfAR programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Davies et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Programme Grants for Applied Research Editor-in-Chief

Professor Paul Little  Professor of Primary Care Research, University of Southampton, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research Group, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk